Harrow Health (HROW)

Executive Summary

Harrow Health (NASDAQ: HROW) is a U.S.-based ophthalmic pharmaceutical company specializing in the development, acquisition, and commercialization of prescription eye care products. The company has successfully transitioned from a compounding pharmacy to a specialty pharmaceutical firm with a growing portfolio of FDA-approved products, including VEVYE (cyclosporine ophthalmic solution) for dry eye disease and IHEEZO (chloroprocaine hydrochloride ophthalmic gel) for ocular anesthesia. Harrow's strategy centers on acquiring late-stage and commercial assets, leveraging its dedicated sales force targeting eye care professionals to drive revenue growth. With a market capitalization of approximately $1.46 billion, the company is well-positioned in the competitive ophthalmic market, though it faces risks from generic competition and pricing pressures. Financially, Harrow has demonstrated improving revenues from recent product launches, but profitability remains a key focus as it scales operations and invests in commercial infrastructure.

Upcoming Catalysts (preview)

• Q2 2026VEVYE Sales Growth and Market Share Update in Q2 2026 Earnings70% success
• Q3 2026Potential Acquisition or In-Licensing of Late-Stage Ophthalmic Asset50% success
• Q4 2026IHEEZO Label Expansion or New Indication Approval30% success